• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Hill International Shares Are Trading Higher By 58%: Here Are 25 Stocks Moving Premarket

    8/17/22 6:06:54 AM ET
    $A
    $APRN
    $APWC
    $ARTL
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Catalog/Specialty Distribution
    Consumer Discretionary
    Get the next $A alert in real time by email

    Gainers

    • Hill International, Inc. (NYSE:HIL) shares rose 58.1% to $2.75 in pre-market trading after the company agreed to be acquired by Global Infrastructure Solutions Inc. for $2.85 per share.
    • Vinco Ventures, Inc. (NASDAQ:BBIG) shares rose 31.9% to $1.49 in pre-market trading. Vinco Ventures shares jumped around 59% on Tuesday after Nasdaq resumed trading in the stock.
    • Endo International plc (NASDAQ:ENDP) rose 24.2% to $0.4594 in pre-market trading after the company filed for bankruptcy.
    • JE Cleantech Holdings Limited (NASDAQ:JCSE) shares rose 23.5% to $2.81 in pre-market trading after jumping over 20% on Tuesday.
    • Cassava Sciences, Inc. (NASDAQ:SAVA) rose 19% to $24.02 in pre-market trading after new filings showed recent insider buying.
    • Bed Bath & Beyond Inc (NASDAQ:BBBY) rose 18.6% to $24.48 in pre-market trading after jumping 29% on Tuesday.
    • Eargo, Inc. (NASDAQ:EAR) rose 16.3% to $2.35 in pre-market trading after climbing 77% on Tuesday. Eargo recently said Q2 EPS results were down year over year.
    • SciSparc Ltd. (NASDAQ:SPRC) rose 13.8% to $1.07 in pre-market trading. Scisparc recently signed a non- binding letter of intent to acquire American food supplements and cosmetics brand in a $20 million deal.
    • Asia Pacific Wire & Cable Corporation Limited(NASDAQ:APWC) rose 12.4% to $2.00 in pre-market trading after jumping 16% on Tuesday.
    • Eros Media World Plc (NYSE:EMWP) rose 12.1% to $1.86 in pre-market trading. Eros Media World entered into Saudi Arabian market through strategic partnership with Arabia Pictures Group.
    • Blue Apron Holdings, Inc. (NYSE:APRN) rose 11.7% to $6.01 in pre-market trading after jumping 16% on Tuesday.
    • Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) rose 11.6% to $0.2724 in pre-market trading after declining 5% on Tuesday. Corbus Pharmaceuticals recently posted a Q2 loss of $0.11 per share.
    • Evogene Ltd. (NASDAQ:EVGN) shares rose 10.2% to $1.30 in pre-market trading. ICL and Evogene reported a strategic collaboration agreement between ICL and Lavie Bio Ltd., a subsidiary of Evogene.
    • FaZe Holdings Inc. (NASDAQ:FAZE) rose 9.6% to $14.60 in pre-market trading after gaining 12% on Tuesday. The company reported Q2 results on Monday.
    • Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares rose 8.5% to $0.7630 in pre-market trading. Dermata Therapeutics recently posted a Q2 loss of $0.24 per share.
    • NewAge, Inc. (NASDAQ:NBEV) rose 7.9% to $0.2695 in pre-market trading.
    • Agilent Technologies, Inc. (NYSE:A) rose 6.3% to $141.10 in pre-market trading after the company reported better-than-expected results for its third quarter and raised its FY22 guidance.


    Don’t forget to check out our premarket coverage here .

    Losers

    • Stronghold Digital Mining, Inc. (NASDAQ:SDIG) shares fell 12.2% to $2.80 in pre-market trading after the company reported worse-than-expected Q2 sales results.
    • Tuesday Morning Corporation (NASDAQ:TUEM) fell 9.6% to $0.3112 in pre-market trading. Tuesday Morning recently reported CFO transition.
    • Cocrystal Pharma, Inc. (NASDAQ:COCP) fell 8.3% to $0.4174 in pre-market trading. Cocrystal Pharma, on Monday, posted a Q2 loss of $0.25 per share.
    • Forza X1, Inc. (NASDAQ:FRZA) fell 7.7% to $7.61 in pre-market trading after jumping 36% on Tuesday.
    • The RealReal, Inc. (NASDAQ:REAL) fell 7.7% to $3.11 in pre-market trading after jumping 22% on Tuesday.
    • Kidpik Corp. (NASDAQ:PIK) shares fell 7.5% to $2.34 in pre-market trading after the company reported worse-than-expected Q2 sales results.
    • Artelo Biosciences, Inc. (NASDAQ:ARTL) fell 7.5% to $5.88 in pre-market trading. Artelo Biosciences shares jumped 46% on Tuesday after the company announced the publication of pre-clinical results of its FABP inhibitor platform.
    • Sanofi (NASDAQ:SNY) fell 6.1% to $42.07 in pre-market trading after the company issued an update on amcenestrant clinical development program.
    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $APRN
    $APWC
    $ARTL

    CompanyDatePrice TargetRatingAnalyst
    Sanofi
    $SNY
    2/12/2026Buy → Neutral
    BofA Securities
    Sanofi
    $SNY
    1/27/2026Neutral
    Citigroup
    Agilent Technologies Inc.
    $A
    1/20/2026$180.00Buy
    HSBC Securities
    Sanofi
    $SNY
    1/16/2026Buy → Neutral
    UBS
    Sanofi
    $SNY
    1/6/2026Overweight → Equal Weight
    Barclays
    Agilent Technologies Inc.
    $A
    1/5/2026$160.00In-line → Outperform
    Evercore ISI
    Agilent Technologies Inc.
    $A
    12/15/2025$165.00Equal Weight → Overweight
    Barclays
    The RealReal Inc.
    $REAL
    12/15/2025Outperform
    William Blair
    More analyst ratings

    $A
    $APRN
    $APWC
    $ARTL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    3/17/26 5:44:21 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Tabacco Joseph J Jr bought $102,200 worth of shares (20,000 units at $5.11) (SEC Form 4)

    4 - BED BATH & BEYOND, INC. (0001130713) (Issuer)

    3/12/26 8:32:43 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Director Frost Phillip Md Et Al bought $19,952 worth of shares (20,000 units at $1.00) (SEC Form 4)

    4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

    2/25/26 4:10:11 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $APRN
    $APWC
    $ARTL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

    For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

    3/28/25 10:17:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

    For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

    2/14/25 3:00:13 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

    Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

    11/4/24 4:49:34 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $APRN
    $APWC
    $ARTL
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Artelo Biosciences Inc.

    SCHEDULE 13G - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

    4/3/26 4:46:28 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    4/3/26 4:05:10 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEFA14A filed by Corbus Pharmaceuticals Holdings Inc.

    DEFA14A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    4/2/26 4:49:55 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $APRN
    $APWC
    $ARTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sanofi downgraded by BofA Securities

    BofA Securities downgraded Sanofi from Buy to Neutral

    2/12/26 7:23:56 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Sanofi

    Citigroup initiated coverage of Sanofi with a rating of Neutral

    1/27/26 8:49:24 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HSBC Securities initiated coverage on Agilent with a new price target

    HSBC Securities initiated coverage of Agilent with a rating of Buy and set a new price target of $180.00

    1/20/26 9:22:21 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $APRN
    $APWC
    $ARTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Chan Anson

    3 - ASIA PACIFIC WIRE & CABLE CORP LTD (0001026980) (Issuer)

    4/3/26 7:23:58 AM ET
    $APWC
    Telecommunications Equipment
    Industrials

    SEC Form 4 filed by Mccaffrey Mark

    4 - TheRealReal, Inc. (0001573221) (Issuer)

    4/2/26 4:19:05 PM ET
    $REAL
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 4 filed by Katz Karen

    4 - TheRealReal, Inc. (0001573221) (Issuer)

    4/2/26 4:15:05 PM ET
    $REAL
    Other Specialty Stores
    Consumer Discretionary

    $A
    $APRN
    $APWC
    $ARTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

    REHOVOT, Israel, April 2, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN)(TASE: EVGN) (the "Company", "Evogene"), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today reported that the Company received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares has been below $1.00 per share for 30 consecutive business days.  The Nasdaq Stock Market Rules provide the Company a period of 180 calendar days to regain compliance. Ac

    4/2/26 4:01:00 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Bed Bath & Beyond, Inc. to Expand Elfa International as a Global Growth Platform Under Existing Leadership

    Bed Bath & Beyond, Inc. (NYSE:BBBY) ("Bed Bath & Beyond" or "BBBY") today announced plans to significantly expand Elfa as a core growth platform within its Home Services Pillar, alongside the signing of definitive agreements that include The Container Store and Closet Works. Founded in Stockholm, Sweden in 1948, Elfa is one of the world's leading modular storage and organization brands, known for its customizable closet systems, shelving solutions, and space optimization products. The brand has built a reputation for durability, flexibility, and design, and has historically been distributed in the United States primarily through The Container Store. As part of this next phase, Anders Ro

    4/2/26 1:09:00 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Letter to Shareholders from Marcus Lemonis, Executive Chairman and CEO: The Growth Phase

    Bed Bath & Beyond, Inc. (NYSE:BBBY) ("Bed Bath & Beyond" or "BBBY") has issued the following letter from Marcus Lemonis, Executive Chairman and Chief Executive Officer of Bed Bath & Beyond: Dear Shareholders, I want to start by sharing how I think about the acquisition of The Container Store, Elfa, and Closet Works, and why I believe this transaction is a critical step for our company. For the past eighteen months, we have studied this business closely. In 2024, we had the opportunity to invest and chose not to move forward due to my concerns around leadership, strategic direction of the brand, and the health of the company's balance sheet. Shortly thereafter, the business entered ban

    4/2/26 8:02:00 AM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $A
    $APRN
    $APWC
    $ARTL
    Leadership Updates

    Live Leadership Updates

    View All

    Groupon Launches Board-Level Artificial Intelligence Committee and Appoints Amit Shah to Board of Directors

    Technology executive and AI entrepreneur to chair new committee as Company positions marketplace for the era of agentic commerceChicago, Illinois--(Newsfile Corp. - March 10, 2026) - Groupon, Inc. (NASDAQ:GRPN) today announced the appointment of Amit Shah to its Board of Directors, effective March 10, 2026, and the formation of a dedicated Artificial Intelligence Committee of the Board. Shah, a seasoned technology executive and AI entrepreneur, will serve as the Committee's inaugural Chair.With this action, Groupon becomes one of the first publicly traded consumer marketplaces to establish a board-level committee dedicated to artificial intelligence. The formation of the Committee reflects t

    3/10/26 4:15:00 PM ET
    $APRN
    $FLWS
    $GRPN
    Catalog/Specialty Distribution
    Consumer Discretionary
    Other Specialty Stores
    Advertising

    The RealReal Announces Board of Directors and Executive Leadership Updates

    SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- The RealReal, Inc. (NASDAQ:REAL), the world's largest online marketplace for authenticated luxury resale, today announced changes to its Board of Directors and executive leadership team, further strengthening the Company's governance and operational leadership as it advances its next phase of growth. Board of Directors Update The RealReal announced the appointment of Jennifer McKeehan to its Board of Directors and the departure of Niki Leondakis from her role as a Board member, both effective March 6, 2026. McKeehan currently serves as Chief Operating Officer of Fanatics Commerce at Fanatics, Inc., and brings extensive experience leading

    3/9/26 4:05:00 PM ET
    $REAL
    Other Specialty Stores
    Consumer Discretionary

    Sanofi announces leadership evolution in Specialty Care Business Unit

    CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity. Brian joined Sanofi in 2017 and has held several senior leadership roles, most recently leading the Specialty Care Global Business Unit and serving as a member of the Executive Committee. During his tenure, Sanofi's Specialty Care strengthened its global position, driven by the launches of key medicines such as Dupixent across multiple indications and geographies. Manuela will lead Sanofi's Spe

    2/17/26 8:30:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $APRN
    $APWC
    $ARTL
    Financials

    Live finance-specific insights

    View All

    Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

    Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral candidate being developed for norovirus treatment and preventionNo approved treatments or vaccines are available for norovirus infection, posing a significant unmet need and contributing to a global economic burden of $60 billion annually BOTHELL, Wash., March 31, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the year ended December 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "We are delighted to report that our norovirus human

    3/31/26 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

    Conference call and webcast: today, March 05, 2026, 9:00 AM ETREHOVOT, Israel, March 5, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the fourth quarter and full year ended December 31, 2025.    Mr. Ofer Haviv, President & CEO of Evogene, stated: "During 2025, we executed a clear and decisive strategic shift. After a comprehensive review of our technology assets, target markets, and capital allocation priorities, we sharpened our focus to drive sustainable long-term value by co

    3/5/26 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    The RealReal Announces Fourth Quarter and Full Year 2025 Results

    Company surpassed $2 billion in GMV, accelerated active buyer growth, and exceeded 2025 financial guidance SAN FRANCISCO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The RealReal, Inc. (NASDAQ:REAL)—the world's largest online marketplace for authenticated, resale luxury goods—today reported financial results for its fourth quarter and full year ended December 31, 2025. Fourth quarter 2025 gross merchandise value (GMV) and total revenue increased 22% and 18%, respectively, compared to the fourth quarter of 2024. Full year 2025 GMV and total revenue increased 16% and 15% respectively, compared to the full year for 2024. Fourth quarter Adjusted EBITDA was $22 million, or 11.3% of total revenue, which

    2/26/26 4:03:00 PM ET
    $REAL
    Other Specialty Stores
    Consumer Discretionary

    $A
    $APRN
    $APWC
    $ARTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by JE Cleantech Holdings Limited

    SC 13D/A - JE Cleantech Holdings Ltd (0001905511) (Subject)

    11/25/24 6:13:31 AM ET
    $JCSE
    Miscellaneous manufacturing industries
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 6:41:20 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care